Background: Crystal-storing histiocytosis (CSH) is a rare disorder occurring in patients with lymphoproliferative diseases, predominantly multiple myeloma and low grade B-cell lymphoma. This report presents the first case of CSH diagnosed on pleural fluid from a patient with multiple myeloma (MM).
Case: A 79-year-old women with IgA kappa MM underwent thoracocenthesis and thoracic drainage because of a pleural effusion. Cytologic and immunocytochemical examination of pleural fluid revealed abundant histiocytic, CD68-positive cells with prominent intracytoplasmic, needlelike, crystalloid inclusions showing strong immunopositivity for IgA heavy and kappa light chains. Identical crystals were observed on an extracellular background. No myeloma infiltration was detected. Two weeks later, examination of new pleural fluid from the patient showed a similar cytologic picture, but, in addition, isolated plasma cell features were identified. They were too few for a meaningful determination of clonality. The patient died I month after the CSH diagnosis.
Conclusion: This case illustrates the value of cytologic examination of serous fluids from patients with plasma cell dyscrasias, not only to evaluate possible infectious or neoplastic causes but also to diagnose CSH.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000326010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ixazomib-induced angioedema.
Int J Hematol
January 2025
Department of Dermatology, Ogawa Red Cross Hospital, 1525 Ogawa, Ogawa-machi, Hiki-gun, Saitama, 355-0397, Japan.
Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Multiple Myeloma.
Clin Cancer Res
January 2025
Bristol-Myers Squibb (United States), Summit, New Jersey, United States.
Purpose: Orvacabtagene autoleucel (orva-cel; JCARH125), a CAR T-cell therapy targeting B-cell maturation antigen (BCMA), was evaluated in relapsed/refractory multiple myeloma (RRMM) patients in the EVOLVE phase 1/2 study (NCT03430011). We applied a modified piecewise model to characterize orva-cel transgene kinetics and assessed the impact of various covariates on its pharmacokinetics (PK).
Experimental Design: The population PK analysis included 159 patients from the EVOLVE study.
Rare cancer survivorship research funding at the National Institutes of Health (NIH), 2017 to 2023.
Cancer Causes Control
January 2025
Office of Cancer Survivorship, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.
Purpose: Rare cancers are defined as those for which there are less than 15 cases per 100,000 in the population annually. While much progress in detection and treatment has been made over the past decade for many rare cancers, less progress has been made in understanding survivorship needs. The objective of this study was to characterize the National Institutes of Health (NIH) cancer survivorship grant portfolio focused on rare cancers and to identify gaps specific to this area of science.
View Article and Find Full Text PDFAre we maintaining minimal residual disease in myeloma?
Leuk Lymphoma
January 2025
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Minimal residual disease (MRD) has emerged as an important prognostic maker in patients with multiple myeloma at different stages of their treatment. Moreover, it is being increasingly incorporated as an endpoint in various clinical trials. Since maintenance therapy is an integral part of myeloma treatment, especially in the upfront setting post autologous transplantation, it is imperative to understand the role of MRD testing in the maintenance stetting.
View Article and Find Full Text PDFDocumentation of International Staging System (ISS) and Revised International Staging System (R-ISS) for Multiple Myeloma at a Tertiary Care Center: A Clinical Audit.
Indian J Clin Biochem
January 2025
Department of Clinical Hematology, Amrita Institute of Medical Sciences, Kochi, Kerala India.
Multiple myeloma (MM) is a highly heterogeneous disease characterised by neoplastic clonal plasma cell proliferation and a wide range of clinical manifestations including skeletal destruction, hypercalcemia, anaemia, renal failure, and immune suppression. Currently accepted and widely used staging criteria for MM patients are the International staging system (ISS) and the Revised International staging system (R-ISS). In order to anticipate outcomes for these patients and to select a risk-adapted therapy, a staging approach that can classify MM patients based on risk at the time of diagnosis itself may be helpful.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!